Literature DB >> 3595539

Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat.

A Kervran, P Blache, D Bataille.   

Abstract

Oxyntomodulin (OXM), an intestinal glucagon-containing peptide extended at its C-terminal end by an octa-peptide, is one of the gut glucagon-like immunoreactants (GLI) or enteroglucagon. The distribution of OXM and glucagon was determined in the gastrointestinal tract and in the plasma of the rat. Reversed-phase HPLC, associated with RRA or RIA, performed with an N-terminally directed glucagon antiserum (GOL), was used. HPLC of intestinal extracts or plasma separated the GOL immunoreactivity into three peaks: two major peaks coeluting with a preparation of rat glicentin (peak I, partially purified from rat intestine) and porcine or rat OXM, respectively, and a smaller peak coeluting with glucagon. The behavior of the three peaks in the analytical systems matched that of glicentin, OXM, and glucagon, respectively, allowing their identification. The concentrations of OXM picomoles per g of tissue) gradually increased from the duodenum (9 +/- 1) to ileum (93 +/- 4), thereafter decreasing in cecum and colon (22 +/- 3). In the gut, OXM, glucagon, and peak I averaged 40%, 1%, and 59% of the total GLI, respectively. OXM was present in significant amounts in the pancreas (18% of GLI) and stomach (27% of GLI), two tissues in which it accounted, together with glucagon, for almost the totality of GLI. In 24 h-fasted rats, plasma concentrations of OXM, glucagon, and peak I, determined after HPLC with GOL antiserum, were 15.1 pM, 8.6 pM, and 12.3 pM, respectively. Two hours after refeeding, both OXM and peak I were significantly increased (P less than 0.05 and P less than 0.02) by a similar factor (2-fold), while glucagon remained unchanged. When the HPLC results were compared with RIA measurement of GLI (GOL antiserum) and glucagon (with a C-terminal glucagon antiserum) in plasma, enteroglucagon (GOL--C-terminal glucagon antiserum immunoreactivities) correlated well with the sum of OXM plus peak I. The combination of HPLC and RRA or RIA allows the unambiguous determination of OXM, glucagon, and glicentin (peak I) in tissues and plasma. In the rat intestine and in the plasma, OXM and glicentin appear roughly in the same ratio and seem to be the major components, if not the totality, of enteroglucagon.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3595539     DOI: 10.1210/endo-121-2-704

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

1.  Oxyntomodulin reduces hydromineral transport through rat small intestine.

Authors:  F Beauclair; B Eto; D Pansu; G Rodier; T Mochizuki; J Martinez; D Bataille; C Jarrousse
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

Review 2.  Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles.

Authors:  J M Conlon
Journal:  Diabetologia       Date:  1988-08       Impact factor: 10.122

Review 3.  From gut changes to type 2 diabetes remission after gastric bypass surgeries.

Authors:  Bing Li; Xinrong Zhou; Jiarui Wu; Huarong Zhou
Journal:  Front Med       Date:  2013-04-04       Impact factor: 4.592

4.  Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions.

Authors:  B Schjoldager; P E Mortensen; J Myhre; J Christiansen; J J Holst
Journal:  Dig Dis Sci       Date:  1989-09       Impact factor: 3.199

5.  Synthesis and secretion of glucagon-like peptide-1 by fetal rat intestinal cells in culture.

Authors:  T H Jackson Huang; P L Brubaker
Journal:  Endocrine       Date:  1995-07       Impact factor: 3.633

6.  Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides.

Authors:  G Rindi; S Efrat; M A Ghatei; S R Bloom; E Solcia; J M Polak
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

7.  N-acetyl oxyntomodulin30-37: pharmacokinetics and activity on gastric acid secretion.

Authors:  C Carles-Bonnet; C Jarrousse; H Niel; J Martinez; M Rolland; D Bataille
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

8.  Purification and sequence of rat oxyntomodulin.

Authors:  N L Collie; J H Walsh; H C Wong; J E Shively; M T Davis; T D Lee; J R Reeve
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

Review 9.  Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

Authors:  David J Grieve; Roslyn S Cassidy; Brian D Green
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

10.  The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.

Authors:  Jennifer R Kosinski; James Hubert; Paul E Carrington; Gary G Chicchi; James Mu; Corey Miller; Jin Cao; Elisabetta Bianchi; Antonello Pessi; Ranabir Sinharoy; Donald J Marsh; Alessandro Pocai
Journal:  Obesity (Silver Spring)       Date:  2012-03-16       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.